REG - Diaceutics PLC - Result of AGM

DiaceuticsAnnouncement

24/06/2024 13:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240624:nRSX6288Ta&default-theme=true

RNS Number : 6288T  Diaceutics PLC  24 June 2024

Diaceutics - Result of Annual General Meeting

 

Belfast and London, 24 June 2024 - Diaceutics PLC
(https://www.diaceutics.com/) (AIM: DXRX), a leading technology and solutions
provider to the pharma and biotech industry, is pleased to announce that all
resolutions proposed at its Annual General Meeting held earlier today, were
duly passed.

The proxy votes received from shareholders in respect of each resolution are
set out below and are available on the Company's website www.diaceutics.com
(http://www.diaceutics.com)

 

 Resolution                                                                            For (excluding at Chair's discretion)     Against                 Total votes cast  Withheld
                                                                                       Number of votes      %                    Number of votes  %                        Number of votes
 1       Ordinary resolution to receive and consider the 2023 Financial Statements     51,263,551           100.00%              0                0.00%  51,263,551

                                                                                                                                                                           Nil

 2       Ordinary resolution to approve the directors' remuneration report             49,660,883           99.65%               172,168          0.35%  51,263,551

                                                                                                                                                                           1,439,500
 3       Ordinary resolution to re-elect Graham Paterson as a director                 51,263,551           100%                 0                0.00%  51,263,551        Nil
 4       Ordinary resolution to re-elect Deborah Davis as a director                   47,743,288           100%                 0                0.00%  51,263,551        3,520,263
 5       Ordinary resolution to re-elect Ryan Keeling as a director                    51,263,551           100%                 0                0.00%  51,263,551        Nil
 6       Ordinary resolution to re-appoint Ernst & Young as auditors                   51,261,890           99.99%               1,661            0.01%  51,263,551

                                                                                                                                                                           Nil
 7       Ordinary resolution to authorise the directors to determine the remuneration  51,263,551           100.00%              0                0.00%  51,263,551
         of the auditors

                                                                                                                                                                           Nil

 8       Ordinary resolution to authorise the directors to allot shares                51,263,551           100.00%              0                0.00%  51,263,551

                                                                                                                                                                           Nil

 9       Special resolution to authorise the directors to issue shares for cash                             99.9%                7,246            0.01%  51,263,551

                                                                                       51,256,305                                                                          Nil
 10      Special resolution to authorise the directors to purchase own shares          51,263,551           100%                 0                0.00%  51,263,551        Nil
 11      Special resolution to cancel the amount standing to the credit of the         51,263,551           100%                 0                0.00%  51,263,551        Nil
         Company's share premium account

Concerning Resolution 11 and the proposed reduction of capital, it was
previously announced in the notes to the Notice of Annual General Meeting that
the initial directions hearing was anticipated to take place on 3 July 2024,
and that the final Court hearing to confirm the capital reduction was
anticipated to take place on 16 July 2024. The Company notes that these dates
have since changed. Diaceutics will confirm the updated timing in due course.

 

Enquiries:

 

 Diaceutics PLC  
 Ryan Keeling, Chief Executive Officer                  Tel: +44 (0)28 9040 6500

 Nick Roberts, Chief Financial Officer                  investorrelations@diaceutics.com (mailto:investorrelations@diaceutics.com)

 Stifel Nicolaus Europe Limited (Nomad & Broker)        Tel: +44 (0)20 7710 7600
 Ben Maddison
 Nick Harland
 Kate Hanshaw

 Alma Strategic Communications                          Tel: +44(0)20 3405 0205
 Caroline Forde                                         diaceutics@almastrategic.com

 Kinvara Verdon

 Kieran Breheny

 

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome.

 

We provide the world's leading pharma and biotech companies with an end-to-end
commercialisation solution for precision medicines through data analytics,
scientific and advisory services enabled by our platform DXRX - The
Diagnostics Network ®.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGMZGZVZDDGDZM